Study reports Parishin B extends lifespan and mitigates proteotoxicity in C. elegans models

Researchers reported that the natural phenolic compound Parishin B extends C. elegans mean lifespan by 23.88% and alleviates disease-associated proteotoxicity, indicating a potential multi-pathway strategy for age-related decline.

A study published in the Journal of Ethnopharmacology reported that Parishin B, a bioactive phenolic constituent of Gastrodia elata Blume, significantly extends the lifespan of wild-type Caenorhabditis elegans, with a 200 μM dose resulting in a 23.88% increase in mean lifespan.

The compound improved several healthspan parameters, including locomotor activity, muscle integrity, mitochondrial morphology, lipid homeostasis, and lipofuscin accumulation.

The research showed that Parishin B alleviated proteotoxicity-associated phenotypes in multiple nematode models of Alzheimer's disease, Parkinson's disease, and Huntington's disease, and protected mammalian PC12 cells from amyloid-beta (Aβ1-42)-induced cytotoxicity.

The researchers determined that the protective effects of Parishin B are dependent on conserved transcription factors DAF-16/FOXO, SKN-1/Nrf2, HSF-1, and HLH-30, which coordinate antioxidant defense, cellular senescence attenuation, and autophagy-lysosome signaling pathways.

The research identifies a specific bioactive agent that explains the historical pharmacological properties of the traditional herb Gastrodia elata Blume in mitigating age-associated functional decline.

By demonstrating dependence on conserved regulators like FOXO, Nrf2, HSF-1, and HLH-30, the study provides a characterized mechanistic framework for Parishin B as a broad-spectrum geroprotector.

The concurrent mitigation of proteotoxicity in models of Alzheimer's and Parkinson's suggests that the pathway activation is relevant to neurodegenerative proteinopathies.

The validation of multi-target transcription factor activation (FOXO, Nrf2, HSF-1, and HLH-30) supports the conceptual development of therapies targeting multiple hallmarks of aging simultaneously.

These preclinical results do not have an immediate impact on clinical pipelines but provide candidate compound structures for researchers developing therapies against cellular senescence and proteotoxicity.

Further studies investigating whether the proteostatic and longevity benefits of Parishin B translate to mammalian in vivo models of aging and neurodegenerative disease.

The identification of upstream binding partners of Parishin B that trigger the activation of the observed stress-response pathways.